• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources

by
November 19, 2026
in Health
Reading Time: 5 mins read
0
German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources

German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive scoping review examining health economic evaluations of health promotion and disease prevention interventions in Germany has revealed that the vast majority of decision-analytic models rely on non-German data sources, exposing substantial methodological variation across the research landscape. Conducted to systematically map and categorize economic evidence generated since 1994, the investigation analyzed 162 eligible primary research studies identified across major biomedical and health services databases. The findings demonstrate that while economic evaluations in prevention have steadily expanded over the past three decades, pervasive data gaps and heterogeneous analytical choices complicate the interpretation of value for healthcare decision-makers. Despite an overwhelming majority of published studies concluding that preventive measures are cost-effective or cost-saving, researchers identified critical weaknesses in analytical perspectives, uncertainty characterization, and the domestic grounding of simulation models.

Health promotion and disease prevention represent central pillars of public health policy aimed at improving population health trajectories and mitigating long-term healthcare expenditure. In Germany, formal political and institutional commitment to prevention increased substantially following the implementation of the Preventive Health Care Act, known as the Präventionsgesetz, in 2015. This legislative framework reinforced statutory health insurance obligations to fund and deploy preventive interventions, while highlighting the need for intersectoral collaboration to foster health equity. However, evaluating preventive strategies involves distinct methodological hurdles compared with standard clinical therapies. Preventive initiatives frequently feature long-term time horizons, diffuse population-level benefits, behavioral outcomes, and broader societal impacts that are difficult to track within conventional trial timelines. As demographic aging and the burden of chronic diseases place ongoing pressure on limited resources, robust economic evaluations are required to prioritize effective and sustainable public health investments.

To rigorously map the evidence base without artificially restricting scope to narrow interventions or comparators, the authors applied the Joanna Briggs Institute scoping review framework alongside the PRISMA Extension for Scoping Reviews checklist, adhering to an a priori registered protocol on the Open Science Framework. The search strategy incorporated the population, concept, and context method, querying Ovid Medline, Ovid Embase, and Clarivate Web of Science from database inception through March 11, 2025. Reviewers implemented blinded, double-reviewer screening of 4,632 identified records, ultimately screening 275 full-text articles against strict inclusion criteria. The review targeted completed primary health economic evaluations focused on the German population and published in German or English, encompassing full comparative analyses of costs and consequences. Studies addressing tertiary prevention, rehabilitation, disease management, or purely pharmacological interventions were explicitly excluded due to substantial overlap with clinical treatment and established regulatory pathways.

The temporal distribution of the 162 included primary studies demonstrates a pronounced upward trend in publication volume over time, with notable peaks observed in 2015, 2017, 2022, and 2024, each accounting for 6.2 percent of the literature. Before 2000, only 10 studies had been published, beginning with initial work in 1994 focused exclusively on screening and vaccination. Across the entire sample, primary preventive interventions formed the primary focus in 53.7 percent of the studies, while secondary preventive interventions, centered on early detection and containment, accounted for 37.7 percent. Interventions explicitly dedicated to broader health promotion represented just 6.2 percent of the corpus, and 2.5 percent could not be definitively categorized due to ambiguous reporting. Most investigations originated directly within Germany, representing 78.4 percent of the studies, while 21.6 percent were conducted through international research collaborations that analyzed German-specific data contexts.

The topical scope of the evaluated literature concentrated heavily on a limited cluster of public health measures across twelve identified health topics. Screening interventions formed the largest single topic, examined in 34.0 percent of the papers, closely followed by vaccination strategies, which comprised 31.5 percent. Lifestyle programs represented the third most frequent category at 12.4 percent, addressing behavioral interventions aimed at promoting healthier diets, physical activity, or related risk-reduction habits. When broken down by specific medical indications, vaccinations against pneumococcal disease were the most frequently investigated issue, appearing in 8.0 percent of studies, with distinct clusters of publications appearing in 2012 and 2024. Colorectal cancer screening appeared consistently from 1996 through 2024, accounting for 7.4 percent of the evaluations, while screening and surgical prevention for breast, cervical, or ovarian cancer accounted for 6.8 percent, exhibiting a distinct acceleration after 2015.

Methodologically, the review identified substantial diversity in analytical frameworks, endpoints, and study designs. Cost-effectiveness analyses using natural or clinical endpoints constituted the most prevalent individual design at 32.1 percent, followed by cost-utility analyses at 13.6 percent, cost-benefit analyses at 12.4 percent, budget impact analyses at 6.2 percent, cost-consequence analyses at 4.9 percent, and cost-minimization analyses at 4.3 percent. Furthermore, 26.6 percent of the publications presented multiple analytical types, led by combined cost-effectiveness and cost-utility studies in 12.4 percent of cases. The vast majority of evaluations, 93.8 percent, were executed as stand-alone economic studies rather than trial-based analyses piggybacked onto clinical effectiveness trials. Target population sizes ranged from a single individual to the entire German population of approximately 83 million people, with a reported median population size of 90,353 individuals, although 24.1 percent of studies omitted population sizes altogether.

The choice of analytical perspective and cost inclusion revealed notable divergences from established health economic recommendations. Despite guidance from the Hanover Consensus advocating a societal perspective for preventive measures with broad community effects, only 14.2 percent of evaluations adopted an exclusively societal perspective, and 35.8 percent incorporated a societal viewpoint either alone or in combination with other perspectives. Instead, a third-party payer perspective, typically that of statutory health insurance, served as the dominant viewpoint, applied in 52.5 percent of all studies. Direct medical costs, including intervention and treatment expenditures, were captured in 95.7 percent of evaluations, whereas indirect costs representing productivity losses were co-considered in 40.1 percent. Where discounting was applied, annual discount rates for costs ranged between 0 percent and 5 percent, centering on a median rate of 3 percent, though 30.3 percent of the studies did not apply discounting to costs.

Outcome measurement and incremental cost-effectiveness ratios showed considerable reliance on quality-adjusted life years, even though German statutory appraisal mechanisms do not officially utilize fixed quality-adjusted thresholds. Across all studies, quality-adjusted life years were reported in 37.0 percent of publications, while clinical endpoints alone appeared in 34.0 percent, and life-years gained appeared in 22.2 percent. Among the 64.2 percent of studies that reported an incremental cost-effectiveness ratio, the ratio was most frequently expressed as incremental costs per quality-adjusted life year gained, accounting for 42.4 percent of all calculated ratios, followed by incremental clinical endpoints at 32.6 percent. Overall, 29.6 percent of the studies applied an explicit cost-effectiveness threshold, with figures ranging from zero to 500,000 euros per quality-adjusted life year gained and a median of 30,000 euros; the most recurring benchmark was 50,000 euros per quality-adjusted life year, used in 11.7 percent of studies.

Decision-analytic modeling served as the analytical foundation for 75.9 percent of the included literature, encompassing 123 distinct simulation studies. Among these modeling papers, Markov cohort models were the most prevalent architecture, applied in 44.7 percent of cases, followed by decision trees in 16.3 percent, microsimulation models in 8.9 percent, and combined Markov and decision-tree structures in 7.3 percent. The simulated time horizons varied dramatically, from six weeks to 120 years, with a median simulated duration of 20 years, and 27.6 percent of models applied a lifetime horizon. Sensitivity analyses were incorporated in 95.1 percent of modeling studies, predominantly univariate deterministic sensitivity analyses in 87.2 percent and probabilistic sensitivity analyses in 47.0 percent. However, 81.3 percent of all model-based evaluations relied partly on non-German data sources to populate model parameters, and 56.1 percent explicitly cited the lack of German-specific epidemiological or utility data as a formal study limitation.

The review authors noted that an overwhelming 85.2 percent of all included evaluations concluded that the analyzed preventive intervention was cost-effective or cost-saving in at least one reported analytical scenario, while only 12.4 percent concluded an intervention was not cost-effective. The authors emphasized that this figure reflects primary author claims rather than standardized base-case re-evaluations, suggesting potential publication bias and the unstandardized application of international benchmarks. Because German healthcare decision-making relies on deliberative assessments of clinical benefit and opportunity costs rather than formal willingness-to-pay thresholds, applying international guidelines directly can be misleading. The researchers concluded that while economic evaluations of prevention are expanding in Germany, advancing policy relevance will require closing domestic data gaps, enhancing methodological consistency, and tailoring reporting frameworks to the specific complexities of preventive and health-promoting interventions.

Subject of Research: Health economic evaluations of health promotion and disease prevention in Germany

Article Title: Health economic evaluation of health promotion and disease prevention in Germany: a scoping review

Article References: Beer, E. J., Kirschneck, M., Coenen, M., & Visscher, R. M. S. (2026). Health economic evaluation of health promotion and disease prevention in Germany: a scoping review. Health Economics Review, 16(1), Article 109. https://doi.org/10.1186/s13561-026-00859-0

Image Credits: AI Generated

DOI: 10.1186/s13561-026-00859-0

Keywords: Health economic evaluation, Health promotion, Disease prevention, Scoping review, Germany, Cost-effectiveness analysis, Cost-utility analysis, Quality-adjusted life years, Decision-analytic modeling, Markov models, Preventive Health Care Act, Third-party payer perspective, Sensitivity analysis, Incremental cost-effectiveness ratio, Vaccination evaluations, Cancer screening

News Source: Ophelia Keating. (November 19, 2026). German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources. Scienmag.

Tags: cancer screeningCost-effectiveness analysisCost-utility analysisdecision-analytic modelingdisease preventionGermanyhealth economic evaluationhealth promotionincremental cost-effectiveness ratioMarkov modelsPreventive Health Care Actquality-adjusted life yearsscoping reviewSensitivity analysisThird-party payer perspectiveVaccination evaluations
Share12Tweet7Share2ShareShareShare1

Related Posts

Pre-Induction Arterial Waveform Profiling May Refine Post-Induction Hypotension Prediction

Pre-Induction Arterial Waveform Profiling May Refine Post-Induction Hypotension Prediction

November 19, 2026
Children With Sickle Cell Disease and Asthma Show Higher Bronchodilator Responsiveness

Children With Sickle Cell Disease and Asthma Show Higher Bronchodilator Responsiveness

November 19, 2026

Medication Failures and Systemic Barriers Drive Avoidable Healthcare Harm in English Prisons

November 19, 2026

Pediatric Traumatic Brain Injury Care Demands Tailored Pharmacotherapy Framework, Review Finds

November 19, 2026

POPULAR NEWS

  • Survey Shows Public Awareness Remains Low as U.S. Mpox Cases Persist

    Survey Shows Public Awareness Remains Low as U.S. Mpox Cases Persist

    29 shares
    Share 12 Tweet 7
  • Single Meningococcal Conjugate Dose Demonstrates Strong Immunity Across Age Groups in Vietnam

    29 shares
    Share 12 Tweet 7
  • German Preventive Health Economic Evaluations Often Rely on Foreign Data Sources

    29 shares
    Share 12 Tweet 7
  • Virtual Community of Practice Strengthens Ukrainian Trauma Care Training During Armed Conflict

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Pre-Induction Arterial Waveform Profiling May Refine Post-Induction Hypotension Prediction

Children With Sickle Cell Disease and Asthma Show Higher Bronchodilator Responsiveness

Medication Failures and Systemic Barriers Drive Avoidable Healthcare Harm in English Prisons

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.